[英语，研究]Safety and immunogenicity of HbSag-pulsed dendritic cells

StephenW

<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01320.x/abstract>

Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic
cells in patients with chronic hepatitis B

S. M. F. Akbar1,2, S. Furukawa1, N. Horiike1, M. Abe1, Y. Hiasa1, M.
Onji1Article first published online: 17 MAY 2010

DOI: 10.1111/j.1365-2893.2010.01320.x
© 2010 Blackwell Publishing Ltd
Issue

Journal of Viral Hepatitis
Volume 18, Issue 6, pages 408–414, June 2011

Summary.  The immune modulator capacity of antigen-pulsed dendritic cells
(DC) has been documented in patients with cancers and in animal models of
chronic viral infections. Cancer antigen-pulsed DC are now used for
treating patients with cancer. But viral antigen-pulsed DC are not used in
chronic viral-infected patients because safety of antigen-pulsed DC has not
been evaluated in these patients. DC were isolated from human peripheral
blood mononuclear cells by culturing with human-grade
granulocyte-macrophage colony stimulating factor and interleukin-4. Human
blood DC were cultured with hepatitis B surface antigen (HBsAg) for 8 h to
prepare HBsAg-pulsed DC. After immunogenicity assessment of HBsAg-pulsed DC
in vitro, five million HBsAg-pulsed DC were administered intradermally to
five patients with chronic hepatitis B (CHB) 1–3 times. HBsAg-pulsed DC
were immunogenic in nature because they produced significantly higher
levels of interleukin-12 and interferon-γ compared to unpulsed DC (P <
0.05). Also, HBsAg-pulsed DC induced proliferation of HBsAg-specific T
lymphocytes in vitro. CHB patients injected with HBsAg-pulsed DC did not
exhibit generalized inflammation, exacerbation of liver damage, abnormal
kidney function, or features of autoimmunity. Administration of
HBsAg-pulsed DC induced anti-HBs in two patients and HBsAg-specific
cellular immunity in 1 patient. This is the first study about preparation
of antigen-pulsed DC using human consumable materials for treating patients
with CHB. Because HBsAg-pulsed DC were safe for all patients with CHB and
had immune modulation capacity in some patients, phase I and phase II
clinical trials with antigen-pulsed DC in CHB and other chronic infections
are warranted.

StephenW

安全性和免疫原性乙肝表面抗原-pulsed 树突状的细胞

在慢性乙​​型肝炎患者

单模光纤Akbar1，2，学古河一，全Horiike 1，安倍晋三1米，华Hiasa 1米
Onji1Article首次出版在线：二○一○年五月十七日

分类号：10.1111/j.1365-2893.2010.01320.x
© 2010布莱克韦尔出版有限公司
发行

作者：病毒性肝炎
18卷第6期，页408-414，2011年6月

综述。抗原的pulsed树突状细胞的免疫调节能力
（直流）已被记录在与癌症患者和动物模型
慢性病毒感染。肿瘤抗原pulsed的DC现在用于
治疗癌症病人。但是病毒抗原pulsed的DC中不使用
慢性病毒感染的病人，因为抗原pulsed的DC安全性还没有
在这些患者中进行了评估。直流人外周血分离
通过培养人外周血单个核细胞与品位
粒细胞巨噬细胞集落刺激因子和白细胞介素- 4。人类
鲜血直流培养与乙型肝炎表面抗原（HBsAg）8小时到
准备乙肝表面抗原脉冲直流。乙肝表面抗原的免疫原性后脉冲直流评估
在体外，500万乙肝表面抗原脉冲直流是皮内到
例慢性乙型肝炎（CHB）患者的1-3倍。乙肝表面抗原脉冲直流
在自然免疫反应，因为他们生产的显着提高
白细胞介素-12和干扰素-γ水平相比，unpulsed直流性（P <
0.05）。此外，乙肝表面抗原pulsedDC诱导增殖乙肝表面抗原特异性T
淋巴细胞在体外。注射乙肝患者与HBsAg脉冲直流没有
展览广义发炎，肝功能损害加重，异常
肾功能，或自身免疫功能。管理
乙肝表面抗原pulsedDC诱导的两名患者抗- HBs和乙肝表面抗原特异性
细胞免疫在1例。这是关于第一项研究的准备
抗原pulsed的DC治疗病人使用人类消耗材料
慢性乙型肝炎。由于乙肝表面抗原脉冲直流是安全的慢性乙肝及所有患者
曾在一些患者的免疫调节能力，第一阶段和第二阶段
与抗原pulsed的DC CHB和其他慢性感染的临床试验
是必要的。